Optimizing Myeloma Treatment: Pomalidomide-based Regimens Compared in Asian Myeloma Network (AMN) Study — a Phase III Analysis of PCd vs. Pd for Relapse or Refractory Myeloma (RRMM) 

Dr. Wee-Joo Chng discusses a randomized phase III trial that compares the use of pomalidomide, cyclophosphamide, and dexamethasone versus (PCd) versus pomalidomide and dexamethasone (Pd) in a population of Asian patients with relapsed/refractory multiple myeloma.

Abstract title:

Randomized Phase III Study of Pomalidomide Cyclophosphamide Dexamethasone (PCd) Versus Pomalidomide Dexamethasone (Pd) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study Presented at ASH 2023   

What is the purpose of this trial?  

This trial focuses on patients with relapsed or refractory multiple myeloma (RRMM) who have limited survival, especially after becoming resistant to lenalidomide and bortezomib. The immunomodulatory drug pomalidomide (pom) has demonstrated improved survival in this patient group. However, the most effective combination with Pom is uncertain, as patients often develop resistance to multiple classes of drugs by the time Pom becomes necessary. 

 The goal of this study is to compare the outcomes of two treatment approaches in Asian patients with RRMM: pomalidomide, cyclophosphamide, and dexamethasone (PCd) versus pomalidomide and dexamethasone (Pd). By evaluating these regimens, the research aims to identify the optimal drug combination that can enhance the treatment effectiveness for RRMM patients in the Asian population, potentially improving their survival and overall outcomes.  

In this video: 

Wee-Joo Chng, MBBS, PhD, FRCPath, FRCP, (National University Cancer Institute — Singapore) discusses this randomized phase III trial that compares the use of PCd versus Pd in a population of Asian patients with relapsed/refractory multiple myeloma.  

Conclusion: 

From the abstract: “This study demonstrated that PCd significantly prolonged progression-free survival, improved overal response rate, and duration of response over Pd in patients with relapsed/refractory multiple myeloma and previous exposure to a proteasome inhibitor and Revlimid (lenalidomide). PCd treatment presents a therapeutic option in this population of patients, with acceptable and manageable safety profile.” 

Trial information: Abstract #1009 

Doctor bio: 

Wee-Joo Chng, MBBS, PhD, FRCPath, FRCP, holds the esteemed positions of Director at the National University Cancer Institute, Singapore, and Group Director of Research at the National University Health System. Renowned as the Yong Loo Lin Professor in Medical Oncology and Vice-Dean of Research at the Yong Loo Lin School of Medicine, he is also a Senior Principal Investigator at the Cancer Science Institute of Singapore, affiliated with the National University of Singapore. Additionally, he serves as the inaugural Executive Director of the Singapore Translational Cancer Consortium. 

Professor Chng's influence extends globally, contributing as a member of various international professional committees, including the IMF’s International Myeloma Working Group and the Asian Myeloma Network. With a prolific research career, he has authored over 300 publications in esteemed journals. Actively engaged in clinical trials and a sought-after speaker at national and international conferences, Professor Chng has garnered recognition for his outstanding contributions to translational research. His accolades include prestigious awards such as the IMF’s Brian G.M. Durie Outstanding Achievement Award, the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, NUHS Pinnacle Award for Research Excellence, NUSMed Researcher of the Year, the National University of Singapore Young Researcher Award, and the Celgene Future Leaders in Haematology Award.